|
|||||
|
|
Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia |
|
| Affiliation: | 2. Clinical Pharmacology & Safety Sciences R&D BioPharmaceuticals, AstraZeneca, Boston, MA;4. Clinical Pharmacology & Safety SciencesCardiovascular, R&D BioPharmaceuticals, AstraZeneca, Gothenburg, Sweden;8. Renal and Metabolism R&D BioPharmaceuticals, AstraZeneca, Gothenburg, Sweden;11. I. M. Sechenov First Moscow State Medical University of the Russian Ministry of Health Moscow, Russia |
| Abstract: | |
| Keywords: | atherosclerosis lipoproteins cholesterol metabolism plasma proprotein convertase subtilisin/kexin type 9 quantitative modeling translational pharmacology |
| 本文献已被 ScienceDirect 等数据库收录！ | |